References

Executive summary of the meeting of the 2018 ASHP Commission on Goals: Focus on Opioids

10.2146/ajhp180672 · 2019 · External reference

Executive summary of the 2019 ASHP Commission on Goals: impact of artificial intelligence on healthcare and pharmacy practice

10.1093/ajhp/zxz205 · 2019 · External reference

Executive summary of the meeting of the 2020 ASHP Commission on Goals: preparing the healthcare workforce for a digital future

10.1093/ajhp/zxaa395 · 2021 · External reference

Executive summary of the meeting of the 2021 ASHP Commission on Goals: Optimizing Medication Outcomes Through Telehealth

10.1093/ajhp/zxac034 · 2022 · External reference

Executive summary of the meeting of the 2022 ASHP Commission on Goals: Optimizing Hospital at Home and Healthcare Transformation

10.1093/ajhp/zxac216 · 2022 · External reference

Executive summary of the meeting of the 2023 ASHP Commission on Goals: Optimizing Medication Therapy Through Advanced Analytics and Data-Driven Healthcare

10.1093/ajhp/zxad261 · 2024 · External reference

Executive summary of the 2024 ASHP Commission on Goals: primary care delivery transformation

10.1093/ajhp/zxae324 · 2024 · External reference

Executive summary of the 2025 ASHP Commission on Goals: Preparing for the Evolving Healthcare Landscape

10.1093/ajhp/zxaf309 · 2026 · External reference

The landscape of cell and gene therapy today

10.1016/j.ymthe.2025.05.006 · 2025 · External reference

Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery

10.1038/s41434-025-00573-2 · 2026 · External reference

Chimeric antigen receptor therapy

10.1056/nejmra1706169 · 2018 · External reference

Pharmacy Futures: Summit on Advanced Therapeutics

10.1093/ajhp/zxaf310 · 2026 · External reference

Unresolved reference

2025 · External reference

From vision to viability: developing infrastructure for cell and gene therapy programs

10.1016/j.jtct.2026.01.002 · External reference

Noncanonical and mortality-defining toxicities of CAR T cell therapy

10.1038/s41591-025-03813-5 · 2025 · External reference

Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis

10.1016/j.eclinm.2025.103267 · External reference

Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances

10.1016/j.jcyt.2024.03.007 · 2024 · External reference

Virtual nursing and the future of workforce sustainability

10.1001/jamanetworkopen.2025.45603 · External reference

Pharmacy-directed coordination of gene and high-cost therapies

10.1093/ajhp/zxaf119 · 2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

The Cell and Gene Therapy Access Model

10.1001/jama.2025.16537 · 2025 · External reference

Gene therapy for sickle cell disease: practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy

10.1016/j.jtct.2026.03.007 · 2026 · External reference

Unresolved reference

External reference

Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research

10.1002/ajh.21880 · 2011 · External reference

Balancing safety and innovation for cell-based regenerative medicine

10.1056/nejmsr1715626 · 2018 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective

10.18553/jmcp.2022.28.10.1138 · 2022 · External reference

Point-of-care CAR T manufacturing solutions: can 1 model fit all?

10.1182/bloodadvances.2024012982 · 2024 · External reference